Bcl-xL antagonist 2

Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) [1][2].

Product Specifications

CAS Number

[1235032-75-3]

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bcl-xl-antagonist-2.html

Purity

98.86

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

O=C(C1=C(CN(C2=NC(C(O)=O)=CS2)CC3)C3=CC=C1)NC4=NC5=C(S4)C=CC=C5

Molecular Formula

C21H16N4O3S2

Molecular Weight

436.51

References & Citations

[1]Koehler MF, et al. Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL. ACS Med Chem Lett. 2014;5 (6) :662-667.|[2]Wang L, et al. Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor. ACS Med Chem Lett. 2020;11 (10) :1829-1836.